Drug Trial Radar · NCT01263925
Prostaglandin E1 in Outpatients With Intermittent Claudication
Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
561
Actual
Start
Apr 2001
Primary completion
Apr 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Dec 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with Intermittent Claudication.
Conditions
- Stage II Peripheral Arterial Occlusive Disease
- Intermittent Claudication Fontaine Stage II PAOD
Interventions
Alprostadil (Prostaglandin E1)Drug
4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours. 4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.
PentoxifyllineDrug
4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets. 4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.
Placebo to Pentoxifylline oralDrug
4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets. 4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.
Placebo to Alprostadil (Prostaglandin E1) intravenousDrug
4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours. 4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at BaselineTime frame: From Baseline to the end of 4 weeks of Interval Treatment (Period 2)
- Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at BaselineTime frame: From Baseline to the end of 6-months Follow-up (Period 3)
- Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at BaselineTime frame: From Baseline to the end of 4 weeks of Daily Treatment (Period 1)
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Aachen, Germany
Site not named
Bad Säckingen, Germany
Site not named
Berlin, Germany
Site not named
Bottrop, Germany
Site not named
Cologne, Germany
Site not named
Dortmund, Germany
Site not named
Dresden, Germany
Site not named
Düsseldorf, Germany
Site not named
Essen, Germany
Site not named
Essen-Steele, Germany
Site not named
Freiburg im Breisgau, Germany
Site not named
Gaggenau, Germany
Site not named
Görlitz, Germany
Site not named
Hamburg, Germany
Site not named
Hanover, Germany
Site not named
Hattingen, Germany
Site not named
Heidelberg, Germany
Site not named
Homburg, Germany
Site not named
Jena, Germany
Site not named
Karlsbad-Lang Ensteinbach, Germany
Site not named
Kassel, Germany
Site not named
Krefeld, Germany
Site not named
Leipzig, Germany
Site not named
Lüneburg, Germany
Site not named
Mannheim, Germany
Site not named
Mannheim-Lindenhof, Germany
Site not named
Mönchengladbach, Germany
Site not named
München, Germany
Site not named
Neuss, Germany
Site not named
Nuremberg, Germany
Site not named
Osnabrück, Germany
Site not named
Papenburg, Germany
Site not named
Regensburg, Germany
Site not named
Seesen, Germany
Site not named
Warendorf, Germany
Site not named
Wuppertal, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.